Shots: Recursion to receive $30M as up front, $50M as equity investment, ~$100M/ program as development and commercial milestones along with royalties on sales. The companies will work on more […]readmore
Tags : Recursion
1. Janssen to Present Updated Results of JNJ-4528 in P-Ib/II CARTITUDE-1 Study for Multiple Myeloma at ASCO 2020 Published: May 14, 2020 | Tags: Janssen, Update, Results, JNJ-4528, P-Ib/II, CARTITUDE-1, Study, […]readmore
Shots: Recursion to get exclusive WW rights to develop and commercialize TAK-733 for the treatment of a hereditary cancer syndrome and related areas of oncology Recursion will utilize its automated […]readmore